Pelion Venture Partners

Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, established in 2004. The company develops a platform of biologic drugs designed to address inflammatory and degenerative diseases, particularly neuro-inflammatory conditions. Artielle's focus includes multiple sclerosis, optic neuritis, methamphetamine addiction, stroke, rheumatoid arthritis, uveitis, age-related macular degeneration, and celiac disease. The company's lead compound, RTL1000, targets T-cell mediated inflammatory diseases by utilizing recombinant T-cell receptor ligands (RTLs). By blocking the action of macrophage migration inhibitory factor through its biological platform, Artielle aims to provide innovative treatments for a range of autoimmune disorders, contributing to advancements in the healthcare industry.